华大基因
(300676)
| 流通市值：187.72亿 | | | 总市值：188.74亿 |
| 流通股本：4.16亿 | | | 总股本：4.18亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,788,516,575.76 | 808,653,640.32 | 3,705,385,018.37 | 2,673,638,742.11 |
| 营业收入 | 1,788,516,575.76 | 808,653,640.32 | 3,705,385,018.37 | 2,673,638,742.11 |
| 二、营业总成本 | 1,663,446,182.11 | 789,867,458.16 | 3,833,902,696.89 | 2,563,396,603.57 |
| 营业成本 | 1,046,013,389.31 | 487,545,233.27 | 2,312,477,246.07 | 1,524,833,168.33 |
| 税金及附加 | 11,093,123 | 6,452,475.39 | 21,192,261.25 | 15,011,728.22 |
| 销售费用 | 326,875,870.23 | 159,095,255.22 | 774,720,864.22 | 545,729,423.14 |
| 管理费用 | 132,297,608.36 | 63,954,032.76 | 329,729,893.05 | 211,678,576.06 |
| 研发费用 | 168,081,652.05 | 88,733,222.89 | 456,868,639.52 | 332,812,703.86 |
| 财务费用 | -20,915,460.84 | -15,912,761.37 | -61,086,207.22 | -66,668,996.04 |
| 其中:利息费用 | 8,922,988.46 | 5,232,897.41 | 36,042,389.86 | 16,921,050.33 |
| 其中:利息收入 | 31,908,040.36 | 16,755,667.16 | 87,397,664.07 | 71,166,396.96 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 25,192,564.11 | 2,624,066.72 | -11,291,407.29 | 17,118,766.81 |
| 加:投资收益 | -5,674,466.99 | 120,434.61 | 12,957,568.69 | 22,010,835.92 |
| 资产处置收益 | 1,480,692.69 | 89,352.79 | -336,061.07 | -883,888.42 |
| 资产减值损失(新) | -9,241,349.13 | -6,059,681.25 | -197,723,135.6 | -8,899,289.67 |
| 信用减值损失(新) | -85,215,318.66 | -29,386,438.05 | -287,904,131.77 | -187,591,909.42 |
| 其他收益 | 10,072,409.49 | 3,924,550.47 | 19,634,206.54 | 12,199,088.27 |
| 四、营业利润 | 61,684,925.16 | -9,901,532.55 | -593,180,639.02 | -35,804,257.97 |
| 加:营业外收入 | 676,963.45 | 98,345.93 | 2,431,633.74 | 1,757,425.28 |
| 减:营业外支出 | 3,831,317.41 | 977,764.33 | 11,589,669.84 | 11,975,498.58 |
| 五、利润总额 | 58,530,571.2 | -10,780,950.95 | -602,338,675.12 | -46,022,331.27 |
| 减:所得税费用 | 10,750,647.83 | -854,105.15 | 35,467,027.5 | -19,791,439.13 |
| 六、净利润 | 47,779,923.37 | -9,926,845.8 | -637,805,702.62 | -26,230,892.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 47,779,923.37 | -9,926,845.8 | -637,805,702.62 | -26,230,892.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,404,587.35 | -9,520,518.11 | -616,655,148.27 | -21,386,988.41 |
| 少数股东损益 | 375,336.02 | -406,327.69 | -21,150,554.35 | -4,843,903.73 |
| 扣除非经常损益后的净利润 | 8,432,380.51 | -19,383,428.75 | -635,695,554.1 | -66,764,682.44 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | -0.02 | -1.48 | -0.05 |
| (二)稀释每股收益 | 0.11 | -0.02 | -1.48 | -0.05 |
| 八、其他综合收益 | -106,772,981.58 | -64,368,684.39 | -79,730,511.73 | -37,070,538.01 |
| 归属于母公司股东的其他综合收益 | -104,548,567.81 | -62,949,121.78 | -77,617,744.85 | -35,540,894.17 |
| 九、综合收益总额 | -58,993,058.21 | -74,295,530.19 | -717,536,214.35 | -63,301,430.15 |
| 归属于母公司股东的综合收益总额 | -57,143,980.46 | -72,469,639.89 | -694,272,893.12 | -56,927,882.58 |
| 归属于少数股东的综合收益总额 | -1,849,077.75 | -1,825,890.3 | -23,263,321.23 | -6,373,547.57 |
| 公告日期 | 2026-08-22 | 2026-04-25 | 2026-04-25 | 2025-10-24 |
| 审计意见(境内) | | | 标准无保留意见 | |